Drug strategies and treatment-resistant schizophrenia

References

• Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977; 14: 260–282
   PubMed Web of Science ®Google Scholar
• Brenner HD, Dencker SJ, Goldstein MJ., Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990; 16: 551–562
   PubMed Web of Science ®Google Scholar
• Keks NA, Copolov DL, Johnson G. Initial Australian experience with the atypical antipsychotic clozapine. Medical Journal of Australia 1993; 159: 638–639
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment of schizophrenia. Schizophrenia Bulletin 1987; 13: 133–156
   PubMed Web of Science ®Google Scholar
• Brown WA, Herz LR. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophrenia Bulletin 1989; 15: 123–129
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990; 16: 563–565
   PubMed Web of Science ®Google Scholar
• Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophrenia Bulletin 1980; 6: 70–87
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• May PRA. Treatment of schizophrenia: a comparative study of five treatment methods. New York: Science House,. 1968
   Google Scholar
• MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986; 148: 128–133
   PubMed Web of Science ®Google Scholar
• Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry 1991; 48: 239–246, [Published erratum appears in Archives of General Psychiatry 1991; 48:642.1
   PubMed Web of Science ®Google Scholar
• May PRA, Dencker SJ., Hubbard JW, Midha KK., Liberman RP. A systematic approach to treatment resistance in schizophrenic disorders. Treatment resistance in schizophrenia. Braunschweig: Friedr. Vieweg Verlag, SJ Dencker, F Kulhanek, 1988; 22–23
   Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis use and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994; 51: 273–279
   PubMed Web of Science ®Google Scholar
• Smith J, Hucker S. Schizophrenia and substance abuse. British Journal of Psychiatry 1994; 165: 13–21
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic non-compliance. Psychiatric Annals 1986; 16: 571–575
   Web of Science ®Google Scholar
• Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 1990; 41: 1203–1211
   PubMedGoogle Scholar
• Mann JJ. How medication compliance affects outcome. Psychiatric Annals 1986; 16: 567–570
   Web of Science ®Google Scholar
• Kane JM. Prevention and treatment of neuroleptic noncompliance. Psychiatric Annals 1986; 16: 576–578
   Web of Science ®Google Scholar
• Gaebel W, Pietzcker A. Prospective study of course of illness in schizophrenia. Part III: treatment and outcome. Schizophrenia Bulletin 1987; 13: 307–316
   PubMed Web of Science ®Google Scholar
• Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Archives of General Psychiatry 1990; 47: 228–236
   PubMed Web of Science ®Google Scholar
• Quitkin F, Rifkin A, Kane JM, Ramos-Lorenzi J, Klein D. Long-acting oral vs injectable antipsychotic drugs in schizophrenics. Archives of General Psychiatry 1978; 35: 889–892
   PubMed Web of Science ®Google Scholar
• Falloon I, Watt DC, Shepherd M. A comparative control trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine 1978; 8: 59–70
   PubMed Web of Science ®Google Scholar
• Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic outpatients: the seven-year follow-up of the MRC fluphenazine/placebo trial. British Journal of Psychiatry 1985; 146: 464–480
   PubMed Web of Science ®Google Scholar
• Crow TJ. Molecular pathology of schizophrenia: more than one disease process?. British Medical Journal 1980; 280: 66–68
   PubMed Web of Science ®Google Scholar
• Johnstone EC, Crow TJ, Frith CD, Camey WMP, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978, i:848-851
   Google Scholar
• Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bulletin 1985; 11: 453–456
   PubMed Web of Science ®Google Scholar
• Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry 1987; 144: 1549–1555
   PubMed Web of Science ®Google Scholar
• Barnes TRE. Issues in the clinical assessment of negative symptoms: editorial review. Current Opinion in Psychiatry 1994; 7: 35–38
   Google Scholar
• van-Kammen DP, Hommer DW, Malas KL. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?. Neuropsychobiology 1987; 18: 113–117
   PubMed Web of Science ®Google Scholar
• Feinberg SS, Kay SR, Elijovich LR, Fiszbein A, Opler LA. Pimozide treatment of the negative schizophrenic syndrome: an open trial. Journal of Clinical Psychiatry 1988; 49: 235–238
   PubMed Web of Science ®Google Scholar
• Petit M, Zann M, Lesieur P, Colonna L. The effect of sulpiride on negative symptoms of schizophrenia [letter],. British Journal of Psychiatry 1987; 150: 270–271
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Speller JC, Curson DA, Pantelis C, Alberts JL. A one-year dose reduction study in chronic schizophrenic inpatients: amisulpride v.v haloperidol. Schizophrenia Research 1992; 6, 107 (abstract)
   Web of Science ®Google Scholar
• Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 1995; 166: 68–72
   PubMed Web of Science ®Google Scholar
• Kane JM, Mayerhoff D. Do negative symptoms respond to pharmacological treatment?. British Journal of Psychiatry 1989; 155 (suppl. 7): 115–118
   Google Scholar
• Lewander T, Westerbergh SE, Morrison D. Clinical profile of remoxipride – a combined analysis of a comparative double blind multicentre trial programme. Acta Psychiatrica Scandinavica. 1990, 82 (suppl. 358):92-98
   Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994; 151: 825–835
   PubMed Web of Science ®Google Scholar
• Rey MJ., Schulz SC, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology 1989; 4: 95–104
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry 1988; 145: 578–583
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr. The deficit syndrome. American Journal of Psychiatry 1994; 151: 327–329
   PubMed Web of Science ®Google Scholar
• Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 1994; 151: 20–26
   PubMed Web of Science ®Google Scholar
• Kolakowska T, Williams AO, Arden M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptic and signs of organic dysfunction. British Journal of Psychiatry 1985; 146: 229–239
   PubMed Web of Science ®Google Scholar
• Murray RM, O'Callaghan E. Neurodevelopmental schizophrenia. Schizophrenia Monitor 1991; 1: 1–3
   Google Scholar
• Castle DJ, Murray RM. The neurodevelopmental basis of sex differences in schizophrenia. Psychological Medicine 1991; 21: 565–575
   PubMed Web of Science ®Google Scholar
• Nelson HE, Pantelis C, Carruthers K, Speller J, Baxendale S, Barnes TRE. Cognitive functioning and symptomatology in chronic schizophrenia. Psychological Medicine 1990; 20: 357–365
   PubMed Web of Science ®Google Scholar
• Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophrenia Bulletin 1991; 17: 197–216
   PubMed Web of Science ®Google Scholar
• Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry. 1987, 48 suppl:13-19
   Google Scholar
• Smith RC, Baumgartner R, Misra CH, Maudlin M. Haloperidol, plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v.v radioreceptor plasma level assay. Archives of General Psychiatry 1984; 41: 1044–1049
   PubMed Web of Science ®Google Scholar
• Cooper TB, Simpson GM, Haher EJ, Bergner PE. Butaperazine pharmacokinetics. Archives of General Psychiatry 1975; 32: 903–905
   PubMed Web of Science ®Google Scholar
• Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DGC, Bourne RC, Gamble SJ. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine 1983; 13: 513–527
   PubMed Web of Science ®Google Scholar
• Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in haloperidol level due to carbamazepine: a complicating medication for schizophrenia. Journal of Clinical Psychopharmacology 1990; 10: 54–57
   PubMed Web of Science ®Google Scholar
• Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 1991; 17: 325–351
   PubMed Web of Science ®Google Scholar
• Angrist B, Schulz SC. Introduction. The neuroleptic nonresponsive patient: characterization and treatment. Washington: American Psychiatric Press, B Angrist, SC Schulz, 1990; xvii–xxviii
   Google Scholar
• Crow TJ, MacMillan JF, Johnson AL, Johnston EC. The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986; 148: 120–127
   PubMed Web of Science ®Google Scholar
• Dencker SJ, May PRA. From chronic mental hospital care to integration in society. Treatment resistance in schizophrenia. Wiesbaden: S.J. Dencker and F. Kulhanek, SJ Dencker, F Kulhanek, 1988; 13–21
   Google Scholar
• Green MF, Kinsbourne M. Subvocal activity and auditory hallucinations: clues for behavioral treatments?. Schizophrenia Bulletin 1990; 16: 617–625
   PubMed Web of Science ®Google Scholar
• Nelson HE, Barnes TRE, Thrasher S. Practical ways of alleviating auditory hallucinations. British Medical Journal 1991; 302: 327
   PubMed Web of Science ®Google Scholar
• Chadwick P, Birchwood M. The omnipotence of voices. A cognitive approach to auditory hallucinations. British Journal of Psychiatry 1994; 164: 190–201
   Google Scholar
• Kingdon D, Turkington D, John C. Cognitive behaviour therapy of schizophrenia. British Journal of Psychiatry 1994; 164: 581–587
   PubMed Web of Science ®Google Scholar
• Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991; 17: 217–245
   PubMed Web of Science ®Google Scholar
• Hirsch SR, Barnes TRE. Clinical use of high-dose neuroleptics. British Journal of Psychiatry 1994; 164: 94–96
   PubMed Web of Science ®Google Scholar
• Kane JM. The use of higher-dose antipsychotic medication: comment on the Royal College of Psychiatists' consensus statement. British Journal of Psychiatry 1994; 164: 431–432
   PubMed Web of Science ®Google Scholar
• Thompson C. The use of higher-dose antipsychotic medication: consensus statement. British Journal of Psychiatry 1994; 164: 448–458
   PubMed Web of Science ®Google Scholar
• Itil TM, Keskiner A, Heinemann L, Han T, Gannen P, Hsu W. Treatment of resistant schizophrenia with extreme high dosage fluphenazine hydrochloride. Psychosomatics 1970; 11: 456–463
   PubMed Web of Science ®Google Scholar
• Quitkin F, Rifkin A, Klein DF. Very high dosage versus standard dosage fluphenazine in schizophrenia: a doubleblind study of non-chronic treatment refractory patients. Archives of General Psychiatry 1975; 32: 1276–1281
   PubMed Web of Science ®Google Scholar
• McCreadie RG, McDonald IM. High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry 1977; 131: 310–316
   PubMed Web of Science ®Google Scholar
• Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestruch IH, Waerens J. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side-effects, serum haloperidol, and serum prolactin. Psychopharmacology 1980; 67: 17–23
   PubMed Web of Science ®Google Scholar
• Kinon BS, Kane JM, Johns JC, Perovich R, Ismi A, Koreen A, Weiden P. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacology Bulletin 1993; 29: 309–314
   PubMedGoogle Scholar
• Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly-admitted schizophrenic patients. Archives of General Psychiatry 1990; 47: 754–758
   PubMed Web of Science ®Google Scholar
• Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Archives of General Psychiatry 1991; 48: 166–170
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 1991; 48: 739–745
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Archives of General Psychiatry 1988; 45: 79–91
   PubMed Web of Science ®Google Scholar
• Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. American Journal of Psychiatry 1980; 137: 16–21
   PubMed Web of Science ®Google Scholar
• Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin 1991; 17: 263–287
   PubMed Web of Science ®Google Scholar
• Seeman P. Schizophrenia as a brain disease: the dopamine receptor story. Archives of Neurology 1993; 50: 1093–1095
   PubMedGoogle Scholar
• Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. British Journal of Psychiatry 1993; 163: 451–455
   PubMed Web of Science ®Google Scholar
• Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D. Idazoxan, an alpha antagonist augments fluphenazine in schizophrenic patients: a pilot study. Journal of Clinical Psychopharmacology 1993; 13: 264–267
   PubMed Web of Science ®Google Scholar
• Stahl SM, Wets KM. Clinical pharmacology of schizophrenia. Schizophrenia: the major issues. London: Heinemann Professional Publishing/Mental Health Foundation, P Bebbington, P McGuffin, 1988
   Google Scholar
• Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bulletin 1991; 17: 289–309
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Novel approaches to the pharmacotherapy of schizophrenia. Drug Development Research 1994; 9: 23–40
   Google Scholar
• Drew L. Clozapine – a remarkable drug. Australasian Psychiatry 1993; 1: 156–157
   Google Scholar
• Kerwin RW. The new atypical antipsychotics. British Journal of Psychiatry 1994; 164: 141–148
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. British Journal of Psychiatry (suppl.) 1992; 17: 30–33
   Google Scholar
• Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–151
   PubMed Web of Science ®Google Scholar
• Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–614
   PubMed Web of Science ®Google Scholar
• Mortimer AM. Clozapine and schizophrenia. Schizophrenia Monitor 1991; 1: 1–4
   Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Journal of Medicine 1991; 324: 746–754
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Watanabe MD, Tran Johnson TK. Clozapine: an atypical antipsychotic agent. Clinical Pharmacology 1989; 8: 691–709
   PubMedGoogle Scholar
• Marder SR, Van-Putten T. Who should receive clozapine?. Archives of General Psychiatry 1988; 45: 865–867
   PubMed Web of Science ®Google Scholar
• Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 1991; 17: 247–261
   PubMed Web of Science ®Google Scholar
• Kane JM. Acute treatment. Antipsychotic drugs and their side-effects. London: Academic Press, TRE Barnes, 1993, 169-181
   Google Scholar
• McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, Frankenberg FR, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. Journal of Clinical Psychiatry 1991; 52: 411–414
   PubMed Web of Science ®Google Scholar
• Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biological Psychiatry 1992; 32: 270–280
   PubMed Web of Science ®Google Scholar
• Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991; 41: 1699–1700
   PubMed Web of Science ®Google Scholar
• Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. Journal of Neuropsychiatry and Clinical Neurosciences 1993; 5: 206–208
   PubMed Web of Science ®Google Scholar
• Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A Finnish epidemic. Acta Psychiatrica Scandinavica 1977; 56: 241–248
   PubMed Web of Science ®Google Scholar
• Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989; 99: S118–S121
   PubMed Web of Science ®Google Scholar
• Andermann B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. European Journal of Clinical Pharmacology 1976; 11: 199–201
   Web of Science ®Google Scholar
• Alvir JMJ, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. Journal of Clinical Psychopharmacology 1994; 14: 87–89
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Johns C, Kane JM, Rai K, Pisciotta AV, Saltz B, Howard A. Clozapine induced agranulocutosis: non-cross reactivity with other psychotropic drugs. Journal of Clinical Psychiatry 1988; 49: 271–277
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Yunis J, Egea E, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 1990; 47: 945–948
   PubMed Web of Science ®Google Scholar
• Oren R, Granat E, Shtrussberg S, Matzner Y. Clozapine- induced agranulocytosis treated with granulocyte macrophage colony stimulating factor. British Journal of Psychiatry 1993; 162: 686–687
   PubMed Web of Science ®Google Scholar
• Seeman P, Guan H, Van Tol HM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441–445
   PubMed Web of Science ®Google Scholar
• Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic- disorders. Journal of Clinical Psychiatry 1994; 55: 255–257
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 1994; 151: 123–125
   PubMed Web of Science ®Google Scholar
• Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced sialorrhoea. British Journal of Psychiatry 1991; 159: 166
   PubMed Web of Science ®Google Scholar
• Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. Journal of Clinical Psychopharmacology 1992; 12: 69–70
   PubMed Web of Science ®Google Scholar
• Warner JP, Harvey CA., Barnes TRE. Clozapine and urinary incontinence. International Clinical Psychopharmacology 1994; 9: 207–209
   PubMed Web of Science ®Google Scholar
• Aronowitz JS, Safferman AZ, Lieberman J A. Management of clozapine-induced enuresis. American Journal of Psychiatry 1995; 152: 472
   PubMed Web of Science ®Google Scholar
• Casey DE. Clozapine: neuroleptic drug-induced EPS and tardive dyskinesia. Psychopharmacology. 1989, 99(suppl):S47-S53
   Google Scholar
• Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry 1992; 53: 439–442
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 1991; 158: 503–510
   PubMed Web of Science ®Google Scholar
• Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacology Series 1988; 5: 74–93
   PubMedGoogle Scholar
• Coward DM. General pharmacology of clozapine. British Journal of Psychiatry (suppl.) 1992; 17: 5–11
   Google Scholar
• Anderson GD, Rebec GV. Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment. Biological Psychiatry 1988; 23: 497–506
   PubMed Web of Science ®Google Scholar
• Borison RL., Diamond BI, Sinha D, Gupta RP, Ajiboye PA. Clozapine withdrawal rebound psychosis. Psychopharmacology Bulletin 1988; 24: 260–263
   PubMedGoogle Scholar
• Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Archives of General Psychiatry 1989; 46: 672
   PubMed Web of Science ®Google Scholar
• Gerlach J. Future treatment of schizophrenia. Psychopharmacology Series 1988; 5: 94–104
   PubMedGoogle Scholar
• Kohler C, Hall U, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatrica Scandinavica (suppl.) 1990; 82: 27–36
   Google Scholar
• Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P, Kerr K, Zorbas A, Hill C, Stedman T, Johnson G, Leibert B, Copolov D, MacKenzie M, Dillenbeck C. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatrica Scandinavica 1994; 90: 358–365
   PubMed Web of Science ®Google Scholar
• Vartiainen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 1993; 87: 114–117
   PubMed Web of Science ®Google Scholar
• Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophrenia Research 1992; 8: 43–49
   PubMed Web of Science ®Google Scholar
• Leysen JE, Gommeren W, Eens A, de-Chaffoy CD, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 1992; 24: 661–670
   Google Scholar
• Silverstone T, Levine S, Freeman HL, Dubini A. Zetidoline, a new antipsychotic: first controlled trial in acute schizophrenia. British Journal of Psychiatry 1984; 145: 294–299
   PubMed Web of Science ®Google Scholar
• Berlant JL. One more look at propranolol for the treatment of refractory schizophrenia. Schizophrenia Bulletin 1987; 13: 705–714
   PubMed Web of Science ®Google Scholar
• Pantelis C, Barnes TRE. Acute exacerbation of psychosis with buspirone?. British Journal of Psychopharmacology 1993; 7: 295–300
   PubMed Web of Science ®Google Scholar
• Cade JFJ. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949; 36: 349–352
   Web of Science ®Google Scholar
• Delva NJ, Letemendia FJJ. Lithium treatment in schizophrenia and schizoaffective disorders. Contemporary issues in schizophrenia. London: Gaskell (Royal College of Psychiatrists), A Kerr, P Snaith, 1986; 381–396
   Google Scholar
• Schulz SC, Kahn EM, Baker RW, Conley RR. Lithium and carbamazepine augmentation in treatment refractory schizophrenia. The neuroleptic non-responsive patient: characterization and treatment. Washington: American Psychiatric Press, B Angrist, SC Schulz, 1990; 109–136
   Google Scholar
• Small JG, Kellams JJ, Milstein V, Moore JA. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry 1975; 132: 1315–1317
   PubMed Web of Science ®Google Scholar
• Growe GA, Crayton JW, Klass DB, Evans H, Stizich M. Lithium in chronic schizophrenia. American Journal of Psychiatry 1979; 136: 454–455
   PubMed Web of Science ®Google Scholar
• Carmen JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. Journal of Clinical Psychiatry 1981; 42: 124–128
   PubMed Web of Science ®Google Scholar
• Lerner Y, Mintzer Y, Shestatsky M. Lithium combined with haloperidol in schizophrenia patients. British Journal of Psychiatry 1988; 153: 359–362
   PubMed Web of Science ®Google Scholar
• Angst J, Weiss P, Grof P, Baastrup C, Schou M. Lithium prophylaxis in recurrent affective disorders. British Journal of Psychiatry 1970; 116: 604–614
   PubMed Web of Science ®Google Scholar
• Braden W, Fink EB, Quails B, Ho CK, Samuels WO. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Research 1982; 7: 69–81
   PubMed Web of Science ®Google Scholar
• Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. Journal of the American Medical Association 1974; 230: 1283–1287
   PubMed Web of Science ®Google Scholar
• Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose-dependent. Journal of Clinical Psychopharmacology 1987; 7: 89–91
   PubMed Web of Science ®Google Scholar
• Ballenger JC. The clinical uses of carbamazepine in affective disorders. Journal of Clinical Psychiatry 1988; 49: 13–21
   PubMed Web of Science ®Google Scholar
• Elphick M. Clinical issues in the use of carbamazepine in psychiatry: a review. Psychological Medicine 1989; 19: 591–604
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing longterm benzodiazepine therapy. Archives of General Psychiatry 1991; 48: 448–452
   PubMed Web of Science ®Google Scholar
• Hakola HP, Laulumaa VA. Carbamazepine in the treatment of violent schizophrenics. Lancet. 1982, i: 1358
   Google Scholar
• Luchins DJ. Carbamazepine for the violent psychiatric patient. Lancet. 1983, i:766
   Google Scholar
• Hakola HP, Laulumaa VA. Carbamazepine in the treatment of violent schizophrenics. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, HM Emrich, T Okuma, AA Muller, 1984; 204–207
   Google Scholar
• Neppe VM. Carbamazepine in nonresponsive psychosis. Journal of Clinical Psychiatry 1988; 49: 22–30
   PubMed Web of Science ®Google Scholar
• Rankel HW, Rankel LE. Carbamazepine in the treatment of catatonia. American Journal of Psychiatry 1988; 145: 361–362
   PubMed Web of Science ®Google Scholar
• Neppe VM. Carbamazepine as adjunctive treatment in non-epileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry 1983; 44: 326–331
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacology Bulletin 1984; 20: 572–584
   PubMedGoogle Scholar
• Luchins DJ. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacology Bulletin 1984; 20: 569–571
   PubMed Web of Science ®Google Scholar
• Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intelligence and Clinical Pharmacology 1987; 21: 355–358
   PubMedGoogle Scholar
• Sramek J, Herrera J, Costa J, Heh C, Tran-Johnson T, Simpson G. A carbamazepine trial in chronic, treatment-refractory schizophrenia. American Journal of Psychiatry 1988; 145: 748–750
   PubMed Web of Science ®Google Scholar
• Okuma T, Yamashita I, Takashi R, Itoh H, Kurihara M, Otsuki R, Watanabe S, Hazamura H, Inanaga KA. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenia and schizoaffective disorders. Acta Psychiatrica Scandinavica 1989; 80: 250–259
   PubMed Web of Science ®Google Scholar
• Heh CWC, Potkin SG, Pickar D, Costa J, Herrera J, Sramek J, DeMet E. Serum homovallinic acid concentrations in carbamazepine-treated chronic schizophrenics. Biological Psychiatry 1989; 25: 639–641
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Jr, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan RW, Waltrip RW, Breier A. Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry 1991; 48: 69–72
   PubMed Web of Science ®Google Scholar
• Kanter GL, Yerevanian BI, Ciccone JR. Case report of a possible interaction between neuroleptics and carbamazepine. American Journal of Psychiatry 1984; 141: 1101–1102
   PubMed Web of Science ®Google Scholar
• Yerevanian BI, Hodgman CH. A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder (letter). American Journal of Psychiatry 1985; 142: 785–786
   PubMed Web of Science ®Google Scholar
• Shukla S, Godwin CD, Long LE, Miller MC. Lithium-carbamazepine neurotoxicity and risk factors. American Journal of Psychiatry 1984; 141: 1604–1606
   PubMed Web of Science ®Google Scholar
• Elphick M, Lyons F, Cowen PJ. Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness. Journal of Psychopharmacology 1988; 2: 1–4
   PubMedGoogle Scholar
• Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?. American Journal of Psychiatry 1985; 143: 650–651
   Web of Science ®Google Scholar
• Post RM. Time course of clinical effects of carbamazepine: Implications for mechanism of action. Journal of Clinical Psychiatry 1988; 49: 35–48
   PubMed Web of Science ®Google Scholar
• Post RM, Weiss SRB. Behavioural pharmacology of carbamazepine: differential effects on kindling. International Clinical Pharmacology 1987; 2: 51–72
   Google Scholar
• Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research 1987; 22: 303–310
   PubMed Web of Science ®Google Scholar
• Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. Archives of General Psychiatry 1984; 41: 165–170
   PubMed Web of Science ®Google Scholar
• Lingjaerde O, Engstrand E, Ellingsen P, Stylo DA, Robak OH. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial. Current Therapeutic Research 1979; 26: 505–514
   Web of Science ®Google Scholar
• Jimerson DC, Van Kammen DP, Post RM, Docherty JP, Bunney WEJ. Diazepam in schizophrenia: a preliminary double-blind trial. American Journal of Psychiatry 1982; 139: 489–491
   PubMed Web of Science ®Google Scholar
• Nestoros JN, Suranyi Cadotte BE., Spees RC, Schwartz G, Nair NP. Diazepam in high doses is effective in schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry 1982; 6: 513–516
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Archives of General Psychiatry 1988; 45: 664–671
   PubMed Web of Science ®Google Scholar
• Kellner R, Wilson RM, Muldawer MD, Pathak D. Anxiety in schizophrenia: the responses to chlordiazepoxide in an intensive design study. Archives of General Psychiatry 1994; 32: 1246–1254
   Google Scholar
• Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Archives of General Psychiatry 1988; 45: 655–659
   PubMed Web of Science ®Google Scholar
• Altamura AC, Mauri MC, Mantero M, Brunetti M. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatrica Scandinavica 1987; 76: 702–706
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacology Bulletin 1992; 28: 291–295
   PubMedGoogle Scholar
• Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatrica Scandinavica 1982; 65: 339–354
   PubMed Web of Science ®Google Scholar
• Holden JM, Itil TM, Keskiner A, Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Comprehensive Psychiatry 1968; 9: 633–643
   PubMed Web of Science ®Google Scholar
• Ruskin P, Averbukh I, Belmaker RH, Dasberg H. Benzodiazepines in chronic schizophrenia. Biological Psychiatry 1979; 14: 557–558
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Rapaport MH, Pickar D. Benzodiazepine augmentation of neuroleptics. The neuroleptic nonresponsive patient: characterization and treatment. Washington: American Psychiatric Press, B Angrist, SC Schulz, 1990; 89–108
   Google Scholar
• Nestoros JN, Nair NPV, Pulman JR, Schwartz G, Bloom D. High doses of diazepam improve neuroleptic resistant chronic schizophrenic patients. Psychopathology 1983; 81: 42–47
   Google Scholar
• Salzman C. The use of ECT in the treatment of schizophrenia. American Journal of Psychiatry 1980; 137: 1032–1041
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992; 18: 515–542
   PubMed Web of Science ®Google Scholar
• Fink M. Clozapine and electroconvulsive therapy. Archives of General Psychiatry 1990; 47: 290–291
   PubMed Web of Science ®Google Scholar
• Friedel RO. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacology Bulletin 1986; 22: 928–930
   PubMedGoogle Scholar
• Gujavarty K, Greenberg LB, Fink M. Electroconvulsive therapy and neuroleptic medication in therapy-resistant positive symptom psychosis. Convulsive Therapy 1987; 3: 185–195
   PubMedGoogle Scholar
• Milstein V, Small JG, Miller MJ, Sharpley PH, Small IF. Mechanisms of action of ECT: schizophrenia and schizo-affective disorder. Biological Psychiatry 1990; 27: 1282–1292
   PubMed Web of Science ®Google Scholar
• Klapheke MM. Follow-up on clozapine and ECT. Convulsive Therapy 1991; 7: 303–305
   PubMedGoogle Scholar
• Landy DA. Combined use of clozapine and electroconvulsive therapy. Convulsive Therapy 1991; 7: 218–221
   PubMedGoogle Scholar
• Safferman AZ, Munne R. Combining clozapine with ECT. Convulsive Therapy 1992; 8: 141–143
   PubMedGoogle Scholar
• Frankenburg FR, Suppes T, McLean PE. Combined clozapine and electroconvulsive therapy. Convulsive Therapy 1993; 9: 176–180
   PubMedGoogle Scholar